نتایج جستجو برای: atovaquone

تعداد نتایج: 456  

2009
Thomas L Perry Prativa Pandey Jennifer M Grant Kevin C Kain

BACKGROUND We report the first case of atovaquone/proguanil treatment failure in severe Plasmodium falciparum malaria acquired by a non-immune traveller to the Indian subcontinent. Recrudescent infection was complicated by neurological involvement 14 days after directly observed therapy with atovaquone/proguanil. Sequence analysis of the plasmodial cytochrome b gene confirmed a contribution of ...

Journal: :The Journal of antimicrobial chemotherapy 2017
Christine Robin Minh Patrick Lê Giovanna Melica Laurent Massias Rabah Redjoul Nihel Khoudour Mathieu Leclerc Florence Beckerich Sébastien Maury Anne Hulin Catherine Cordonnier

Objectives Atovaquone is one of the alternatives to trimethoprim/sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients. In volunteers, there was wide inter-individual variability in atovaquone bioavailability. The aim of this study was to assess the plasma concentrations of atovaquone in immunocompromised patients under PCP prophylaxis. Metho...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005
Walter T Hughes Wayne M Dankner Ram Yogev Sharon Huang Mary E Paul Midnela Acevedo Flores Mark W Kline Lee-Jen Wei

BACKGROUND Trimethoprim-sulfamethoxazole (TMP-SMZ) has been used extensively for the prevention of Pneumocystis carinii (also referred to as "Pneumocystis jiroveci") pneumonia (PCP) and other opportunistic infections in human immunodeficiency virus (HIV)-infected children. Because the efficacy of TMP-SMZ for treatment of bacterial infections is limited, it is sometimes poorly tolerated, and the...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2001
A Llanos-Cuentas P Campos M Clendenes C J Canfield D B Hutchinson

The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (Malarone) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru. Patients were initially randomized to receive 1,000 mg atovaquone and 400 mg proguanil hydrochloride daily for 3 days (n=15) or 1,500 mg chloroquine (base) over a 3 day per...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998
G D Shanks D M Gordon F W Klotz G M Aleman A J Oloo D Sadie T R Scott

Currently recommended prophylactic regimens for Plasmodium falciparum malaria are associated with a high incidence of adverse events and/or suboptimal efficacy. In a double-blind, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of atovaquone/proguanil hydrochloride (250 mg/100 mg per tablet) to eliminate preexisting infection. Immedia...

Journal: :The Journal of antimicrobial chemotherapy 1997
O Cirioni A Giacometti G Scalise

The anti-Pneumocystis carinii activity of atovaquone, dapsone and sulphamethoxazole alone and combined with dihydrofolate reductase (DHFR) inhibitors and macrolides was investigated against five clinical isolates of P. carinii. The susceptibility tests were performed by inoculation of the organisms on to cell monolayer and parasite count after 72 h incubation at 37 degrees C. Culture plates wer...

2016
Lauren A. Lawres Aprajita Garg Vidya Kumar Igor Bruzual Isaac P. Forquer Isaline Renard Azan Z. Virji Pierre Boulard Eduardo X. Rodriguez Alexander J. Allen Sovitj Pou Keith W. Wegmann Rolf W. Winter Aaron Nilsen Jialing Mao Douglas A. Preston Alexia A. Belperron Linda K. Bockenstedt David J. Hinrichs Michael K. Riscoe J. Stone Doggett Choukri Ben Mamoun

Human babesiosis is a tick-borne multisystem disease caused by Babesia species of the apicomplexan phylum. Most clinical cases and fatalities of babesiosis are caused by Babesia microti Current treatment for human babesiosis consists of two drug combinations, atovaquone + azithromycin or quinine + clindamycin. These treatments are associated with adverse side effects and a significant rate of d...

Journal: :Molecular and biochemical parasitology 2006
Jacques J Kessl Kevin H Ha Anne K Merritt Steven R Meshnick Bernard L Trumpower

0 d ondii is a widespread disease affecting primarily immunocomromised and pregnant individuals [1]. Atovaquone is a recently ntroduced anti-malarial compound with broad spectrum activty against various apicomplexan parasites [2–5] including T. ondii [6]. Approved by the FDA in 1995, this drug is a potent nd specific inhibitor of the cytochrome bc1 complex [7], an ssential respiratory enzyme pr...

Journal: :Experimental parasitology 2005
Louisa McRobert Shende Jiang Andrew Stead Glenn A McConkey

The shikimate pathway for aromatic biosynthesis presents a target for antimalarial drug development as this pathway is absent from animals. This study extends previous work on inhibitors of the shikimate pathway, by examining their interaction with the antimalarial drugs pyrimethamine and atovaquone. Combinations of atovaquone with several shikimate analogues exhibited synergistic effects. Thes...

Journal: :Antimicrobial agents and chemotherapy 2002
K Jones S A Ward

The synergistic potential of a range of biguanides, their triazine metabolites, tetracyclines, and pyrimethamine in combination with atovaquone has been assessed. All five biguanides tested interacted synergistically with atovaquone against Plasmodium falciparum in vitro. All of the other compounds tested were either additive or antagonistic.

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید